Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Lower Gastrointestinal (GI) Series market assumes an urgent part in the symptomatic scene, focusing in on the representation of the lower part of the stomach related framework. It fills in as an important device for individual and surveying conditions like colorectal cancers, challenging gut diseases, and primary indiscretions.
The rising pervasiveness of colorectal diseases, including colorectal cancer growth, diverticulitis, and Crohn's illness, is a critical driver of the Lower GI Series market. As the worldwide weight of these diseases expands, the interest for successful analytic devices, for example, Lower GI Series methods is similarly developing.
Expanding awareness of colorectal cancer growth and the execution of screening programs are affecting market elements. Legislatures and healthcare associations are underlining the significance of early identification, driving the interest for Lower GI Series as a critical part of colorectal malignant growth screening.
Virtual Colonoscopy, a harmless imaging strategy, is gaining footing inside the Lower GI Series market. This method, otherwise called CT colonography, offers an option in contrast to customary colonoscopy, giving detailed pictures of the colon without the requirement for invasive measures.
Challenges connected with the expense of strategies and openness in certain regions impact market elements. Endeavors to address these difficulties, like the execution of financially smart imaging arrangements and the development of healthcare foundation, assume a part in market growth.
Radiation exposure reduction drives are an eminent pattern in the Lower GI Series market. Movements in imaging technologies center around limiting radiation openness without compromising analytic quality, addressing concerns connected with the potential dangers related with radiation-based techniques.
The market faces rivalry from elective indicative techniques, like colonoscopies and adaptable sigmoidoscopies. The decision between these systems relies upon factors like patient inclination, clinical signs, and the availability of cutting-edge imaging technologies.
Lower GI Series Market Highlights:
Lower GI Series Market Overview
Lower GI Series Market Size was valued at USD 248.46 Billion in 2023. The Global Lower GI Series industry is projected to grow from USD 268.11 Billion in 2024 to USD 478.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.15% during the forecast period (2024 - 2032).
Lower GI series is a lower gastrointestinal series or barium enema; it is one of the medical procedure, which helps in diagnosis of diseases and abnormalities related to human large intestine and rectum. Moreover, major companies are focusing on investment in R&D to introduce efficient methods as well as innovative devices since they are under constant pressure to provide new and cost-effective methods.
According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 60-70 million people are affected by either major or minor GIT diseases in America. The number is continuously increasing due to poor diet and increasing aging population. The lower GI series market is driven majorly due to increasing prevalence of GI diseases, gastric cancer, and changing lifestyle. Additionally, developing technologies, increasing cost-effective methods, and the government’s support for research have boosted the growth of this market. However, availability of alternative therapies may hamper the growth of the market during the review period.
Lower GI Series Market Segmentation
The lower GI series market is segmented on the basis of by applications, types of tests, and end user.
On the basis of applications, it is segmented into gastroenteritis, colon polyps, tumor, strictures crohn's disease, ulcerative colitis, and others.
On the basis of types of test, it is segmented into double-contrast test and single-contrast test.
On the basis of end users, this market is segmented into hospitals, clinics, and laboratories.
Regional Analysis of the Lower GI Series Market
On the regional basis, the market is segmented into the America, Europe, Asia Pacific, and the Middle East & Africa. The America owns a significant share in the global market as a result of huge investment in research and development in the healthcare sector and its strong economic conditions for research and development. Increasing patient base and geriatric population to boost the growth of the Lower GI Series Market.
Europe is the second largest market followed by Asia Pacific on account of increasing technological improvements. The technological improvements will result in higher efficiency and accuracy for diagnosis. Asia Pacific is the fastest growing market due to increasing prevalence of communicable diseases in this region. India and China have started investing in research and development of healthcare sector, which will boost the Lower GI Series Market growth of this region.
Key Players in the Lower GI Series Market
Some of the key players in Lower GI Series Market are:
- Eisai (US)
- Cadila Pharmaceuticals
- PeaceHealth
- Purdue Pharma L.P.
- Alfa Wassermann
- NOVADAQ
- Mount Sinai Beth Israel
- AstraZeneca
- Ironwood Pharmaceuticals Inc.
Intended Audience
- Manufacturing industries
- Pharmaceutical industry
- Biotechnology companies
- Research and development (R&D) companies
- Government research laboratories
- Medical research institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
